{"filing":{"accession_number":"0001140361-26-025050","cik":"0000874015","ticker":"IONS","company_name":"IONIS PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"ef20076110_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/874015/000114036126025050/ef20076110_8k.htm"},"events":[{"id":5202,"run_id":4556,"accession_number":"0001140361-26-025050","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Ionis disclosed positive clinical trial data from the CORE-OLE extension study of olezarsen, including longer-term hepatic MRI-PDFF results showing mean HFF levels returning toward baseline after 24 months of treatment and continued favorable safety profile. While this is a clinical update rather than a traditional material event category (earnings, M\u0026A, restatement, etc.), the disclosure of significant trial results for a late-stage drug candidate would materially affect investor assessment of the company's pipeline and commercial prospects, particularly given the high patient retention rate (\u003e90%) and the focus on a severe indication (sHTG).","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":6536,"accession_number":"0001140361-26-025050","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Ionis disclosed positive clinical trial data from the CORE-OLE extension study of olezarsen, including longer-term hepatic MRI-PDFF results showing mean HFF levels returning toward baseline after 24 months of treatment and continued favorable safety profile. While this is a clinical update rather than a traditional material event category (earnings, M\u0026A, restatement, etc.), the disclosure of significant trial results for a late-stage drug candidate would materially affect investor assessment of the company's pipeline and commercial prospects, particularly given the high patient retention rate (\u003e90%) and the focus on a severe indication (sHTG).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-12T18:21:07.534689+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6536,"accession_number":"0001140361-26-025050","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Ionis disclosed positive clinical trial data from the CORE-OLE extension study of olezarsen, including longer-term hepatic MRI-PDFF results showing mean HFF levels returning toward baseline after 24 months of treatment and continued favorable safety profile. While this is a clinical update rather than a traditional material event category (earnings, M\u0026A, restatement, etc.), the disclosure of significant trial results for a late-stage drug candidate would materially affect investor assessment of the company's pipeline and commercial prospects, particularly given the high patient retention rate (\u003e90%) and the focus on a severe indication (sHTG).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-12T18:21:07.534689+00:00","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-06-12"}]}